Characterization of HIV-infectedpatients Anti-HAV ≥ 20mIU/mL (n=23) Anti-HAV <20mIU/mL (n=6) p
Median age at study inclusion (years)
(range)
12.4
(9.7, 16.8)
13.5
(10.9 , 16.2)
0.450*
Median age at primary HAV immunization (years) (range) 5.13
(1.92, 9.32)
6.01
(3.18, 8.96)
0.628*
Median age at beginning of ARV
(years) (range)
1.73
(0.27,5.63)
3.18
(1.67, 4.34)
0.196*
Female
(%)
11
(47.8)
3
(50)
0.924†
Z score H/A                                                   
(range)
- 0.88
(-2.21, + 1.06)
- 0.40
(-1.51, +1.44)
0.205*
Z score BMI
(range)
- 0.10
(-2.6, +1.7)
- 0.36
(-2.64, +0.89)
0.726*
Clinical category
N/A/B (%)
C (%)

20 (87.0)
3 (13.0)

5 (83.3)
1 (16.7)
0.819†


0.119†
Immunologic category
1/2 (%)
3 (%)

21(91.3)
2 (8.7)

4 (66.7)
2 (33.3)
Median CD4+ T cells before starting ART
(range)
1532
(315, 4245)
720
(520, 1580)
0.058*
Median nadir CD4+ T cells count (cells/mm3)
(range)
485
(140, 1179)
200
(5, 559)
0.019*
Median currentlog VL (copies/mL)
(range)
3.0
(1.0, 4.97)
4.0
(2.16, 5.7)
0.067*
Median log VL before starting ART
(range)
5.2
(4.1 , 7.1)
4.9
(3.3, 5.2)
0.216*
Number of patients with undetectable current VL (%) 6/23 (26) 0/6 (0) 0.160†
Number of patients starting ART aged ≤ 1 year (%)
Number of patients without ART at primary immunization (%)
8/23 (34.7)
0/23 (0)
0/6 (0)
1/6 (16.6)
0.089†
0,207†
Number of patients without ART at the current study (%) 4/23 (17.4) 3/6 (50.0) 0.096†
* Mann Whitney test, † Fisher’s exact test; ART: Antiretroviral therapy; VL: HIV viral load
Table 1: Clinical, immunological and virological aspects of HIV-infected patients from HAV seropositive (Anti-HAV ≥20 mIU/mL) and HAV seronegative
Goto home»